Regeneron (REGN 2.50%), a leading biotechnology firm known for its work in immunology and ophthalmology, reported Q2 2025 earnings on August 1, 2025. The headline news: the company posted Non-GAAP earnings per share of $12.89, towering nearly 52.9$8.43. Reported GAAP revenue hit $3.68 billion, also ahead of the projected$3.29 billion (GAAP), and up 3.6% year-over-year. This performance was set against ongoing manufacturing and regulatory hurdles, particularly in i ...